Viridian Therapeutics, Inc.\De (VRDN) Stock Price & Analysis
Viridian Therapeutics, Inc.\De (VRDN) rose 0.05% to USD 19.27 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
VRDN last closed at USD 19.26; the session ranged USD 19–19.45 on volume of 1,515,453 shares. Market capitalization is $2.13B, with a 52-week range of USD 13.18–34.29 (NCM). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 19.27 |
|---|---|
| Change | ▲ 0.05% (up) |
| Previous Close | USD 19.26 |
| Open | USD 19.39 |
| Day Range | USD 19 – 19.45 |
| 52-Week Range | USD 13.18 – 34.29 |
| Volume | 1,515,453 shares |
| Market Cap | $2.13B |
| Exchange | NCM |
Technical Analysis (VRDN)
Nexqual's technical model rates VRDN "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.76 (neutral) |
| vs SMA50 | Above (USD 17.66) |
| MACD | 0.41 (positive) |
Analyst Ratings (VRDN)
Wall Street analysts rate VRDN "Strong Buy" based on 16 analysts, with a mean price target of USD 36.13 (range USD 22–50), per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 36.13 |
| High Target | USD 50 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 17 / 0 / 0 |
Earnings (VRDN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.03 |
| Revenue Estimate | $22,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.9 vs est -1.08 ▲ beat |
| 2025-12-31 | USD -1.08 vs est -1 ▼ miss |
| 2025-09-30 | USD -0.34 vs est -0.94 ▲ beat |
| 2025-06-30 | USD -1 vs est -0.98 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (VRDN)
| Total Revenue | $70.92M |
|---|---|
| Revenue Growth (YoY) | +95.80% |
| Gross Margin | +0.00% |
| Operating Margin | -82389.36% |
| Profit Margin | +0.00% |
| ROE | -58.14% |
| Debt / Equity | 8.39 |
| Current Ratio | 15.15 |
| Total Cash | $762.18M |
| Total Debt | $53.35M |
| Free Cash Flow | $-182.55M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (VRDN)
Nexqual rates Viridian Therapeutics, Inc.\De's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $762M cash vs $53M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$183M, burning cash |
| Efficiency | Critical — ROE -58%, ROA -33.3% |
Ownership (VRDN)
| Insider Ownership | +0.14% |
|---|---|
| Institutional Ownership | +111.93% |
| Shares Outstanding | 110.43M |
| Float | 97.76M |
| Short % of Float | +16.29% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (VRDN)
Viridian Therapeutics, Inc.\De is led by Stephen F. Mahoney (age 54), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:08 UTC.
| CEO, President & Director | Stephen F. Mahoney (age 54) |
|---|---|
| Chief Financial Officer | Seth Harmon (age 44) |
| Chief Operating Officer | Thomas W. Beetham (age 55) |
| Co-Founder & Chairman of Scientific Advisory Board | Eric N. Olson |
Major Backers & Investors (VRDN)
Notable institutional backers of Viridian Therapeutics, Inc.\De include FMR, LLC, Fidelity, Bellevue Group AG, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.92% |
| Fidelity | 8.06% |
| Bellevue Group AG | 6.53% |
| Fairmount Funds Management LLC | 3.8% |
| Venrock Adviser, LLC | 3.77% |
| Price (T.Rowe) Associates Inc | 3.11% |
| Paradigm Biocapital Advisors LP | 3.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.49% |
| State Street | 8.32% |
| Vanguard Group | 7.06% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
From Viridian Therapeutics, Inc.\De's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
- It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
- The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED.
- Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | USD 57.36 | ▲ 1.96% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
| IDYA | IDEAYA Biosciences, Inc. | USD 35.4 | ▲ 1.14% |
| VERA | Vera Therapeutics, Inc. | USD 35.45 | ▼ 1.68% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.